audeo indicative ipo pricing is now public, page-25

Can someone please help me to understand the following statement, in relation to the HyACT platform and for example, HA-Irinotecan, which is currently being trialled in patients with 2nd/3rd line metastatic colorectal cancer?

"The primary endpoint will be reached when 350 patients have experienced disease progression or death, which it is anticipated in the second half of 2013."

What I cannot rationalise is that if HyACT allows Irinotecan to be more effective, this will extend the life of many patients. Surely a more realistic endpoint should take into consideration the mean life expectancy of a patient on Irinotecan, versus one on HA-Irinotecan, while obviously allowing for (any) additional side-effects.

The above "primary endpoint" statement, taken on its face value (by my layman's logic), implies that the more effective the HyACT platform is, the longer the trial and therefore the longer it will take to get to market.

This seems hypocritical to me (as a non-scientist). I must surely be missing something...

...?